Fidaxomicin - Generic Drug Details

What are the generic sources for fidaxomicin and what is the scope of freedom to operate?

Fidaxomicin is the generic ingredient in two branded drugs marketed by Cubist Pharms Llc and Actavis Labs Fl, and is included in three NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fidaxomicin has one hundred and fifty-eight patent family members in thirty-six countries.

There are two drug master file entries for fidaxomicin. Two suppliers are listed for this compound.

Summary for fidaxomicin

International Patents:	158
US Patents:	5
Tradenames:	2
Applicants:	2
NDAs:	3
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	41
Clinical Trials:	41
Patent Applications:	2,542
Drug Prices:	Drug price trends for fidaxomicin
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for fidaxomicin
What excipients (inactive ingredients) are in fidaxomicin?	fidaxomicin excipients list
DailyMed Link:	fidaxomicin at DailyMed

See drug prices for fidaxomicin

Recent Clinical Trials for fidaxomicin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical College of Wisconsin	EARLY_PHASE1
McGill University Health Centre/Research Institute of the McGill University Health Centre	PHASE2
Medical University of Warsaw	NA

See all fidaxomicin clinical trials

Pharmacology for fidaxomicin

Drug Class

Macrolide Antibacterial

Anatomical Therapeutic Chemical (ATC) Classes for fidaxomicin

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for FIDAXOMICIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DIFICID	Tablets	fidaxomicin	200 mg	201699	1	2015-05-27

US Patents and Regulatory Information for fidaxomicin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cubist Pharms Llc	DIFICID	fidaxomicin	TABLET;ORAL	201699-001	May 27, 2011	AB	RX	Yes	Yes
Cubist Pharms Llc	DIFICID	fidaxomicin	TABLET;ORAL	201699-001	May 27, 2011	AB	RX	Yes	Yes	7,863,249*PED				Y
Cubist Pharms Llc	DIFICID	fidaxomicin	FOR SUSPENSION;ORAL	213138-001	Jan 24, 2020		RX	Yes	Yes	9,808,530*PED				Y
Cubist Pharms Llc	DIFICID	fidaxomicin	TABLET;ORAL	201699-001	May 27, 2011	AB	RX	Yes	Yes	8,859,510*PED				Y
Cubist Pharms Llc	DIFICID	fidaxomicin	TABLET;ORAL	201699-001	May 27, 2011	AB	RX	Yes	Yes	7,378,508*PED				Y

EU/EMA Drug Approvals for fidaxomicin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Tillotts Pharma GmbH	Dificlir	fidaxomicin	EMEA/H/C/002087Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.Dificlir granules for oral suspension is indicated for the treatment of Clostridioides  difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to < 18 years of age.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.	Authorised	no	no	no	2011-12-05

International Patents for fidaxomicin

Country	Patent Number	Title	Estimated Expiration
Eurasian Patent Organization	201591226	КОМПОЗИЦИЯ ТИАКУМИЦИНОВЫХ СОЕДИНЕНИЙ
Cyprus	1121459
European Patent Office	2125850
South Korea	102181474
New Zealand	601347	Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof

Supplementary Protection Certificates for fidaxomicin

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1539977	C 2015 015	Romania		PRODUCT NAME: FIDAXOMICIN; NATIONAL AUTHORISATION NUMBER: EU/1/11/733/001, EU/1/11/733/002, EU/1/11/733/003, EU/1/11/733/004; DATE OF NATIONAL AUTHORISATION: 20111205; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/733/001, EU/1/11/733/002, EU/1/11/733/003, EU/1/11/733/004; DATE OF FIRST AUTHORISATION IN EEA: 20111205
1539977	C201530022	Spain		PRODUCT NAME: FIDAXOMICINA; NATIONAL AUTHORISATION NUMBER: EU/1/11/733/001-004; DATE OF AUTHORISATION: 20111207; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/733/001-004; DATE OF FIRST AUTHORISATION IN EEA: 20111207
1539977	C20150013 00220	Estonia		PRODUCT NAME: FIDAKSOMITSIIN;REG NO/DATE: EU/1/11/733 07.12.2011
1539977	122015000026	Germany		PRODUCT NAME: FIDAXOMICIN; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205
1539977	C300727	Netherlands		PRODUCT NAME: FIDAXOMICINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111205

Market Dynamics and Financial Trajectory for Fidaxomicin

Last updated: July 27, 2025

Introduction

Fidaxomicin, marketed primarily under the brand name Dificid, is a macrocyclic antibiotic designated for the treatment of Clostridioides difficile infections (CDI). As a novel therapy with a targeted spectrum and a favorable safety profile, fidaxomicin has significantly impacted the landscape of CDI management. This analysis explores the underlying market dynamics, competitive positioning, regulatory environment, and financial outlook that shape the trajectory of fidaxomicin within the pharmaceutical ecosystem.

Market Overview and Epidemiology

Clostridioides difficile infection remains a leading cause of antibiotic-associated diarrhea worldwide, especially among hospitalized and elderly populations. The CDC estimates approximately 500,000 cases annually in the United States alone, with a significant morbidity and mortality burden [1]. The demand for effective and safe CDI therapeutics continues to grow, driven by increasing antibiotic resistance, recurrent infection rates, and heightened awareness.

Fidaxomicin distinguishes itself by exhibiting superior efficacy in reducing recurrence rates compared to traditional agents like vancomycin and metronidazole. Its targeted mechanism minimizes disruption to gut microbiota, contributing to a lower recurrence rate, a critical factor in clinical decision-making (Louie et al., 2011).

Market Dynamics

Competition and Therapeutic Landscape

The CDI drug market is predominantly populated by vancomycin and metronidazole, with fidaxomicin positioned as a superior but premium therapy. While traditional therapies dominate due to cost advantages, clinical evidence demonstrating lower recurrence rates have bolstered fidaxomicin's prominence among high-risk and refractory cases.

However, the market faces challenges from generic versions of vancomycin and the advent of new antibiotics under development. The patent protection for fidaxomicin has a limited lifespan, with patent expiry anticipated in the coming years, opening pathways for generic manufacturers to penetrate the market and exert downward pressure on pricing [2].

Patient Population and Prescription Trends

Fidaxomicin's utilization is concentrated among patient subsets with high recurrence risk or contraindications to standard therapies. Despite its clinical benefits, usage remains constrained by cost and formulary restrictions. Payor acceptance varies, with some healthcare systems advocating for its use based on cost-effectiveness analyses considering recurrence reduction and hospitalization rates.

Regulatory Factors and Reimbursement Policies

Regulatory approvals across key markets—United States, Europe, Japan—have set the stage for fidaxomicin's adoption. Nonetheless, reimbursement remains a critical determinant. In the U.S., Centers for Medicare & Medicaid Services (CMS) and private insurers have either restricted or negotiated for favorable pricing, affecting market penetration.

Pricing and Market Penetration Strategies

Fidaxomicin commands a premium price—approximately $3,500 - $4,500 for a standard treatment course—reflecting its R&D investment and clinical benefits. Limited access due to high cost restricts widespread use, predominantly reserving it for high-risk patients. Efforts to expand indications and generate real-world data may influence broader payer acceptance.

Financial Trajectory and Revenue Outlook

Current Revenue Performance

Fidaxomicin's revenues have exhibited modest growth since launch, with peak sales reaching approximately $250 million annually globally (2017–2018) [3]. The U.S. remains the largest market, owing to high CDI prevalence and clinical practice patterns favoring newer agents.

Growth Drivers

• Expansion of Indications: Trials investigating fidaxomicin for other enteric infections or prophylactic use could augment demand.
• Medical Guidelines: Favorable inclusion in clinical guidelines emphasizing recurrence reduction may promote prescription.
• Market Expansion: Increasing adoption in Europe and Asia, particularly in countries with high CDI burden, presents growth opportunities.

Potential Market Constraints

• Generic Entrypoints: Patent expiration will open the market to generics, threatening price erosion and revenue decline.
• Cost-Effectiveness Debates: Payers scrutinize the incremental benefit relative to costs, potentially limiting formulary placements.

Forecasting the Future

Analysts project a gradual decline in fidaxomicin’s market share post-patent expiry, barring new indications or combination therapies that justify premium pricing. Nevertheless, as healthcare systems prioritize personalized and microbiome-preserving therapies, fidaxomicin’s niche position may sustain its revenue trajectory for the foreseeable future.

Regulatory and Market Outlook

Emerging data supporting fidaxomicin’s role in reducing recurrent CDI and its microbiome-sparing benefits could influence guideline endorsements and payer policies. Additionally, efforts to develop next-generation formulations or biosimilars may reshape competitive dynamics and financial prospects.

Key Factors Influencing Financial Trajectory

• Pharmacoeconomic evaluations emphasizing long-term cost savings through reduced recurrences.
• Patent and exclusivity periods directing revenue peaks and declines.
• Market expansion into emerging regions with high CDI incidence.
• Competitive innovations and generics impacting pricing strategies.

Conclusion

Fidaxomicin's market dynamics are shaped by its clinical niche, pricing strategy, patent status, and evolving reimbursement landscape. While current revenues reflect its premium positioning, the impending expiration of patents and increasing generic competition forecast a challenging near-term financial outlook. Strategic investments in expanding indications, bolstering clinical evidence, and engaging payors will be pivotal for sustaining revenue streams.

---

Key Takeaways

• Fidaxomicin remains a high-priced, clinically valuable therapy for CDI, especially for recurrent cases.
• Market growth is constrained by high costs and patent expiry, with generics poised to enter soon.
• Payer policies and clinical guideline endorsements will significantly influence adoption rates.
• Expanding indications and geographical markets could mitigate revenue decline.
• Long-term financial success hinges on balancing innovation, cost-effectiveness, and market access strategies.

---

FAQs

1. What factors have limited fidaxomicin’s widespread adoption despite clinical advantages?
High cost and restrictive formulary policies limit its use mainly to high-risk or refractory patients, preventing broader adoption in standard practice.

2. How imminent is the patent expiration for fidaxomicin, and what are its implications?
Patent expiration is anticipated within the next 1–2 years in major markets, opening opportunities for generic manufacturers and potential price erosion.

3. Are there ongoing clinical trials that could expand fidaxomicin’s approved uses?
Yes. Studies investigating its prophylactic role, efficacy for other enteric infections, and combination therapies are underway, which may enhance its therapeutic scope.

4. How does fidaxomicin compare cost-wise to traditional therapies for CDI?
While more expensive upfront, lower recurrence rates could translate to healthcare savings, but payor acceptance depends on cost-effectiveness analyses and reimbursement policies.

5. What strategies can manufacturers employ to maintain revenue post-patent expiry?
Developing new formulations, obtaining approval for additional indications, and engaging in biosimilar markets are key strategies to sustain financial viability.

---

References:

[1] CDC. (2022). Clostridioides difficile Infection (CDI). Centers for Disease Control and Prevention.

[2] Epstein, L. G., & Snydman, D. R. (2013). The future of fidaxomicin in the management of Clostridium difficile infection. Infectious Diseases in Clinical Practice, 21(1), 13–16.

[3] IQVIA Business Intelligence. (2018). Global Food, Drug, and Medical Device Market Reports.